Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 64, Issue 2, 2005, Pages 229-234

  Braun, J ^a,b,c   Brandt, J ^c   Listing, J ^d   Zink, A ^d   Alten, R ^e   Burmester, G ^f   Gromnica Ihle, E ^g   Kellner, H ^h   Schneider, M ⁱ   Sorensen H ^j   Zeidler, H ^k   Sieper, J ^b,d  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Centre of Rheumatology Ruhrgebiet   (Germany)

^d German Natl Research Cent for   (Germany)

^e Schlosspark Clinic   (Germany)

^f HUMBOLDT UNIVERSITY   (Germany)

^g Hospital Berlin Buch   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j Immanuel Hospital   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; INFLIXIMAB; LIVER ENZYME;

ACCIDENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; BATH AS FUNCTIONAL INDEX; BATH AS METROLOGY INDEX; BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRY EYE; FATIGUE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; HEADACHE; HERPES SIMPLEX; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MENORRHAGIA; MUSCULOSKELETAL DISEASE; MYALGIA; PANCREATITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SHORT FORM 36; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VAGINITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RANGE OF MOTION, ARTICULAR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19944432148     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.025130     Document Type: Article

References (15)

1. Wanders A, van der Heijde D, Landewé R, Behier JM, Calin A, Olivieri I, et al. Inhibition of radiographic progression in ankylosing spondylitis (AS) by continuous use of NSAIDs. Arthritis Rheum 2003;48(Suppl):S233.
2. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in treatment of ankylosing spondylitis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39:2004-12.
3. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropothies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001;13:245-9.
4. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
5. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
6. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
7. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
8. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garret SL, Calin A, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
9. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992;30:473-83.
10. Medical Outcome Trust. How to score the SF-36 Health Survey, 2nd ed. Boston: Medical Outcome Trust, 1994.
11. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
12. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria far short-term improvement after anti-TNFα therapy in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44, doi:10.1136/ard.2003. 016717 [Published Online First 25 Mar 2004].
13. Listing J, Schlittgen R. A nonparametric test for random dropouts. Biometrical Journal 2003;45:113-27.
14. Baert F, Noman M, Vermeire S, van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
15. Maini R, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.